NCT02603887 · FLOW

Participant flow

Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma · Source last updated 2026-07-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

description
Pembrolizumab 200 mg, 30 minute IV infusion every 21 days up to 24 cycles if equal or higher than minor response and without serious adverse events after 8 cycles
id
FG000
title
Treatment (Pembrolizumab)

periods

drop Withdraws
reasons
group Id
FG000
num Subjects
4
type
Adverse Event
reasons
group Id
FG000
num Subjects
1
type
Disease progression
milestones
achievements
group Id
FG000
num Subjects
12
type
STARTED
achievements
group Id
FG000
num Subjects
12
type
Cycle 1
achievements
group Id
FG000
num Subjects
7
type
Cycle 8
achievements
group Id
FG000
num Subjects
7
type
COMPLETED
achievements
group Id
FG000
num Subjects
5
type
NOT COMPLETED
title
Stage 1
drop Withdraws
reasons
group Id
FG000
num Subjects
1
type
FDA guidance
milestones
achievements
group Id
FG000
num Subjects
1
type
STARTED
achievements
group Id
FG000
num Subjects
1
type
Cycle 1
achievements
group Id
FG000
num Subjects
0
type
Cycle 8
achievements
group Id
FG000
num Subjects
0
type
COMPLETED
achievements
group Id
FG000
num Subjects
1
type
NOT COMPLETED
title
Stage 2

pre Assignment Details

20 participants were consented. 13 participants were treated at MD Anderson Cancer Center. An additional participant started stage 2 that did not participate in Stage 1"

recruitment Details

Enrollment period was between July 2016 and August 2017

Complete source fields